Please register **until 22nd of September 2021** at https://survey.zdv.uni-mainz.de/index.php/916321



Organisation Dr. Ann-Kathrin Herrmann Scientific Coordinator

Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz) University Medical Center Mainz Langenbeckstr. 1 55131 Mainz

Phone: +49 (0) 6131 - 175487 Email: uct-science@uct-mainz.de

Sponsored by





uct Universitäres Centrum für Tumorerkrankungen MAINZ



The UCT Mainz presents

3rd Mini-Symposium in Translational Oncology (MiTraC)

"Emerging Concepts in Immuno-Oncology & DNA Damage"

28th of September 2021 | 1.00 - 6.00 pm Online Symposium



uct Universitäres Centrum für Tumorerkrankungen MAINZ

The UCT Mainz presents

3rd Mini-Symposium in Translational Oncology (MiTraC)

Dear friends & colleagues,

we are happy to welcome you to the 3rd UCT Mainz Mini-Symposium in Translational Oncology (MiTraC) sponsored by Merck KGaA.

In this Mini-Symposium series we aim to address important areas of cancer research linked to translational oncology. Within this format, we have the opportunity to invite outstanding scientists to present novel findings, techniques and ideas.

The topic of this year's symposium is "Emerging Concepts in Immuno-Oncology & DNA Damage", which covers two prominent scientific core areas of the UCT Mainz. The talks will cover major interests of many research groups working at the UCT Mainz and our partnering institutions and clinics.

We wish you a pleasant time and an interesting symposium with lots of new insights and discoveries!

With best regards,

Thomas Kindler Head of the UCT Mainz Ann-Kathrin Herrmann Scientific Coordinator UCT Mainz

Program

12.30 Uhr Start Log in & Assembly of Participants

13.00 Uhr Welcome

Thomas Kindler, UCT Mainz & Ralph Lindemann, Merck KGaA

- Session 1: Emerging Technologies in Translational Oncology Chair: Matthias Gaida, Mainz
- 13.15 Uhr Highly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometry Bernd Bodenmiller, Zurich
- 13.55 Uhr Liquid biopsies to guide cancer treatment Nitzan Rosenfeld, Cambridge
- 14.35 Uhr Exploring the relationship between germline variation, somatic mutations and the immune response against cancer cells Eduard Porta Pardo, Barcelona
- 15.15 Uhr Coffee Break
- Session 2: Targeting DNA Damage & Repair 2.0 Chair: Thomas Hofmann, Mainz
- 15.45 Uhr DNA Damage Response Research at Merck Frank Zenke, Darmstadt
- 16.25 Uhr Mutational signatures and homologous recombination repair deficiency Daniel Hübschmann, Heidelberg
- 17.05 Uhr Mapping synthetic lethality networks to study DNA repair Daniel Durocher, Toronto
- 17.45 Uhr Closing Remarks & Summary